Views & Analysis Rethinking access barriers to innovation Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs.
Views & Analysis 2021 market access prospects for Germany The market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – is ten years old, and that milestone prompts reflections on what has worked well and
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
